Advertisement
Australia markets close in 3 hours 45 minutes
  • ALL ORDS

    7,775.60
    -123.30 (-1.56%)
     
  • ASX 200

    7,522.40
    -119.70 (-1.57%)
     
  • AUD/USD

    0.6369
    -0.0057 (-0.88%)
     
  • OIL

    85.80
    +3.07 (+3.71%)
     
  • GOLD

    2,426.10
    +28.10 (+1.17%)
     
  • Bitcoin AUD

    94,769.69
    -1,881.50 (-1.95%)
     
  • CMC Crypto 200

    1,255.94
    +370.40 (+39.36%)
     
  • AUD/EUR

    0.5997
    -0.0034 (-0.56%)
     
  • AUD/NZD

    1.0876
    +0.0001 (+0.01%)
     
  • NZX 50

    11,757.86
    -78.18 (-0.66%)
     
  • NASDAQ

    17,394.31
    -99.31 (-0.57%)
     
  • FTSE

    7,877.05
    +29.06 (+0.37%)
     
  • Dow Jones

    37,775.38
    +22.07 (+0.06%)
     
  • DAX

    17,837.40
    +67.38 (+0.38%)
     
  • Hang Seng

    16,196.50
    -189.37 (-1.16%)
     
  • NIKKEI 225

    36,874.53
    -1,205.17 (-3.16%)
     

Better Gene-Editing Stock: Editas Medicine vs. Bluebird Bio

Better Gene-Editing Stock: Editas Medicine vs. Bluebird Bio

Editas Medicine (NASDAQ: EDIT) and Bluebird Bio (NASDAQ: BLUE) are both beaten-down gene-editing stocks. Editas' shares are down by 65% in the last 12 months, whereas Bluebird's have fallen by 40%. The question of which company is the better gene-editing stock for long-term investment is largely a question of which of these two biotechs has a higher chance of surviving over the next three years.